Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)

TPEX:4111 Revenue

Chi Sheng Pharma & Biotech had revenue of 356.76M TWD in the quarter ending March 31, 2026, with 11.62% growth. This brings the company's revenue in the last twelve months to 1.41B, up 16.08% year-over-year. In the year 2025, Chi Sheng Pharma & Biotech had annual revenue of 1.38B with 18.11% growth.

• Revenue (ttm): 1.41B
• Revenue Growth: +16.08%
• P/S Ratio: 1.27
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 1.79B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.38B	211.04M	18.11%
Dec 31, 2024	1.17B	104.57M	9.86%
Dec 31, 2023	1.06B	-82.21M	-7.19%
Dec 31, 2022	1.14B	120.78M	11.81%
Dec 31, 2021	1.02B	42.94M	4.38%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 27, 2026

Data Sources Report a data error